toxylact: a07aa05 polymyxin b

The first professional lActological database in the word


The ATC class A07AA05 refers to oral polymyxin B, a non‑absorbed intestinal antibiotic used as an anti‑infective agent in the gastrointestinal tract, and it is generally compatible with breastfeeding when used in usual oral doses because systemic maternal exposure is minimal.atcddd.fhi+1

Drug and ATC classification

Polymyxin B is a polypeptide bactericidal antibiotic produced by strains of Bacillus polymyxa and active primarily against Gram‑negative bacteria.ldh.la+1
Within the ATC system it is classified under A07AA (intestinal anti‑infective antibiotics) with the specific code A07AA05 for oral polymyxin B formulations used in enterocolitis and related conditions.atcddd.fhi+1
Oral polymyxin B in this group is considered a “reserve” antibiotic in stewardship systems, reflecting its use when limited alternatives are available or for specific indications.list.essentialmeds

Pharmacology and toxicology

Polymyxin B acts by binding to lipopolysaccharides and phospholipids in the outer membrane of Gram‑negative bacteria, disrupting membrane integrity and increasing permeability, which leads to rapid cell death.drugbank+1
It shows potent activity against organisms such as Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., Acinetobacter spp., Salmonella, Shigella, Escherichia coli and Pasteurella, but has little or no activity against most Gram‑positive bacteria, fungi, or Proteus spp.ldh.la+1
Systemic polymyxin B (parenteral or intrathecal) is associated with dose‑dependent nephrotoxicity and neurotoxicity (paresthesias, dizziness, ataxia), but these adverse effects are markedly less relevant for non‑absorbed oral intestinal formulations.rxlist+1

Use in lactation

The Drugs and Lactation Database (LactMed) and specialized lactation‑pharmacology sources use oral, minimally absorbed intestinal antibiotics as typical examples of medicines with very low transfer into breast milk and negligible risk to the breastfed infant.ncbi.nlm.nih+1
In the case of A07AA05 polymyxin B, oral administration results in poor gastrointestinal absorption in the mother, so maternal plasma concentrations and subsequent passage into milk are expected to be extremely low.ldh.la+1
On this basis, oral polymyxin B used as an intestinal anti‑infective is generally considered compatible with breastfeeding, and lactation can usually continue without interruption while monitoring the infant for nonspecific gastrointestinal symptoms such as changes in stool pattern.europeanjournalofmidwifery+1

Clinical considerations in breastfeeding women

For breastfeeding patients, it is important to confirm that the prescribed product is an oral intestinal formulation of polymyxin B (A07AA05) rather than a systemic preparation, because systemic use carries a higher risk of maternal toxicity and potentially higher drug levels in milk.atcddd.fhi+1
Usual precautions in lactation include using the lowest effective dose for the shortest necessary duration, avoiding concomitant nephrotoxic or neurotoxic drugs, and assessing maternal renal function when there is any suspicion of systemic exposure.drugbank+1
In line with major professional recommendations, most maternal medications—including intestinally acting antibiotics with minimal absorption—are not absolute contraindications to breastfeeding, and individualized risk–benefit assessment is preferred

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.